← All trials
NCT03621761
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2018
- Primary completion
- Apr 30, 2021
- Completion date
- Apr 30, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 330
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of MichiganLead sponsor
- University of MichiganReponsible party - principal investigator
- University of MichiganOverall official - principal investigator
- University of WashingtonCollaborator
- National Multiple Sclerosis SocietyCollaborator
- Patient-Centered Outcomes Research InstituteCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.